Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Here's What Happened

Key Points

• Telix Pharmaceuticals (NASDAQ:TLX) experienced a significant increase in trading volume, with 82,897 shares exchanged, marking a 35% rise from the previous session.
• Analysts have a consensus "Moderate Buy" rating for TLX, with a price target averaging around $22.33, supported by recent upgrades from firms like Wedbush and HC Wainwright.
• Large institutional investors have been acquiring positions in Telix Pharmaceuticals, with at least five firms purchasing new stakes during recent quarters, indicating growing interest in the stock.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares saw unusually-strong trading volume on Tuesday . Approximately 82,897 shares changed hands during mid-day trading, an increase of 35% from the previous session's volume of 61,593 shares.The stock last traded at $9.21 and had previously closed at $9.05.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TLX shares. HC Wainwright decreased their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Finally, Wedbush reissued an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Telix Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $21.33.

Telix Pharmaceuticals Trading Down 1.2%

The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. The company's 50 day moving average is $12.54 and its 200-day moving average is $15.44.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Pier Capital LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth about $3,037,000. Russell Investments Group Ltd. bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth about $975,000. Jane Street Group LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth about $564,000. ABC Arbitrage SA bought a new stake in shares of Telix Pharmaceuticals in the 1st quarter worth about $451,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth about $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.